1
|
Ginestra G, Gervasi T, Mancuso F, Bucolo F, De Luca L, Gitto R, Barreca D, Mandalari G. Evaluation of the In Vitro Antifungal Activity of Novel Arylsulfonamides against Candida spp. Microorganisms 2023; 11:1522. [PMID: 37375025 DOI: 10.3390/microorganisms11061522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Revised: 04/28/2023] [Accepted: 06/05/2023] [Indexed: 06/29/2023] Open
Abstract
The antifungal activity of molecules belonging to the arylsulfonamide chemotype has previously been demonstrated. Here, we screened arylsulfonamide-type compounds against a range of Candida spp. and further established the structure-activity relationship based on a "hit compound". A series of four sulfonamide-based compounds, N-(4-sulfamoylbenzyl) biphenyl-4-carboxamide (3), 2,2-diphenyl-N-(4-sulfamoylbenzyl) acetamide (4), N-(4-sulfamoylphenethyl) biphenyl-4-carboxamide (5) and 2,2-diphenyl-N-(4-sulfamoylphenethyl) acetamide (6), were tested against the American Type Culture Collection (ATCC) and clinical strains of C. albicans, C. parapsilosis and C. glabrata. Based on the fungistatic potential of prototype 3, a further subset of compounds, structurally related to hit compound 3, was synthesized and tested: two benzamides (10-11), the related amine 4-[[(4-4-((biphenyl-4-ylmethylamino)methyl) benzenesulfonamide (13) and the corresponding hydrochloride, 13.HCl. Both amine 13 and its hydrochloride salt had fungicidal effects against Candida glabrata strain 33 (MFC of 1.000 mg/mL). An indifferent effect was detected in the association of the compounds with amphotericin B and fluconazole. The cytotoxicity of the active compounds was also evaluated. This data could be useful to develop novel therapeutics for topical use against fungal infections.
Collapse
Affiliation(s)
- Giovanna Ginestra
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98166 Messina, Italy
| | - Teresa Gervasi
- Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98125 Messina, Italy
| | - Francesca Mancuso
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98166 Messina, Italy
| | - Federica Bucolo
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98166 Messina, Italy
| | - Laura De Luca
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98166 Messina, Italy
| | - Rosaria Gitto
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98166 Messina, Italy
| | - Davide Barreca
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98166 Messina, Italy
| | - Giuseppina Mandalari
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98166 Messina, Italy
| |
Collapse
|
2
|
Ghafuri H, Rashidizadeh A, Gorab MG, Jafari G. Copper(II)-β-cyclodextrin immobilized on graphitic carbon nitride nanosheets as a highly effective catalyst for tandem oxidative amidation of benzylic alcohols. Sci Rep 2022; 12:2331. [PMID: 35149698 PMCID: PMC8837611 DOI: 10.1038/s41598-022-05363-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2021] [Accepted: 01/11/2022] [Indexed: 11/09/2022] Open
Abstract
In this study, an efficient catalyst based on graphitic carbon nitride nanosheets (CN) and copper(II) supported β-cyclodextrin (β-CD/Cu(II)) was synthesized and used for tandem oxidative amidation of benzylic alcohols. In this regard, CN was functionalized by β-CD/Cu(II) via 1,3-dibromopropane linker (CN-Pr-β-CD/Cu(II)). The prepared catalyst was characterized using FT-IR, XRD, FE-SEM, EDS, TGA, ICP-OES, BET, and TEM analyses. CN-Pr-β-CD/Cu(II) was subsequently applied in a direct oxidative amidation reaction and it was observed that different benzyl alcohols were converted to desire amides with good to excellent efficiency. This reaction was performed in the presence of amine hydrochloride salts, tert-butyl hydroperoxide (TBHP), and Ca2CO3 in acetonitrile (CH3CN) under nitrogen atmosphere. CN-Pr-β-CD/Cu(II) can be recycled and reused five times without significant reduction in reaction efficiency.
Collapse
Affiliation(s)
- Hossein Ghafuri
- Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology, 16846-13114, Tehran, Iran.
| | - Afsaneh Rashidizadeh
- Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology, 16846-13114, Tehran, Iran
| | - Mostafa Ghafori Gorab
- Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology, 16846-13114, Tehran, Iran
| | - Ghazaleh Jafari
- Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology, 16846-13114, Tehran, Iran
| |
Collapse
|
12
|
Mizuno A, Miura S, Watanabe M, Ito Y, Yamada S, Odagami T, Kogami Y, Arisawa M, Shuto S. Three-Dimensional Structural Diversity-Oriented Peptidomimetics Based on the Cyclopropylic Strain. Org Lett 2013; 15:1686-9. [DOI: 10.1021/ol400469w] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Akira Mizuno
- Faculty of Pharmaceutical Sciences, Center for Research and Education on Drug Discovery, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan, PRISM BioLab Co., Ltd., 4259-3, Nagatsuta-cho, Midori-ku, Yokohama 226-8510, Japan, and D.D.P. Corporation, 1097-3, Kashiya, Kannami-cho, Shizuoka 419-0112, Japan
| | - Shiho Miura
- Faculty of Pharmaceutical Sciences, Center for Research and Education on Drug Discovery, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan, PRISM BioLab Co., Ltd., 4259-3, Nagatsuta-cho, Midori-ku, Yokohama 226-8510, Japan, and D.D.P. Corporation, 1097-3, Kashiya, Kannami-cho, Shizuoka 419-0112, Japan
| | - Mizuki Watanabe
- Faculty of Pharmaceutical Sciences, Center for Research and Education on Drug Discovery, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan, PRISM BioLab Co., Ltd., 4259-3, Nagatsuta-cho, Midori-ku, Yokohama 226-8510, Japan, and D.D.P. Corporation, 1097-3, Kashiya, Kannami-cho, Shizuoka 419-0112, Japan
| | - Yoshihiko Ito
- Faculty of Pharmaceutical Sciences, Center for Research and Education on Drug Discovery, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan, PRISM BioLab Co., Ltd., 4259-3, Nagatsuta-cho, Midori-ku, Yokohama 226-8510, Japan, and D.D.P. Corporation, 1097-3, Kashiya, Kannami-cho, Shizuoka 419-0112, Japan
| | - Shizuo Yamada
- Faculty of Pharmaceutical Sciences, Center for Research and Education on Drug Discovery, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan, PRISM BioLab Co., Ltd., 4259-3, Nagatsuta-cho, Midori-ku, Yokohama 226-8510, Japan, and D.D.P. Corporation, 1097-3, Kashiya, Kannami-cho, Shizuoka 419-0112, Japan
| | - Takenao Odagami
- Faculty of Pharmaceutical Sciences, Center for Research and Education on Drug Discovery, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan, PRISM BioLab Co., Ltd., 4259-3, Nagatsuta-cho, Midori-ku, Yokohama 226-8510, Japan, and D.D.P. Corporation, 1097-3, Kashiya, Kannami-cho, Shizuoka 419-0112, Japan
| | - Yuji Kogami
- Faculty of Pharmaceutical Sciences, Center for Research and Education on Drug Discovery, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan, PRISM BioLab Co., Ltd., 4259-3, Nagatsuta-cho, Midori-ku, Yokohama 226-8510, Japan, and D.D.P. Corporation, 1097-3, Kashiya, Kannami-cho, Shizuoka 419-0112, Japan
| | - Mitsuhiro Arisawa
- Faculty of Pharmaceutical Sciences, Center for Research and Education on Drug Discovery, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan, PRISM BioLab Co., Ltd., 4259-3, Nagatsuta-cho, Midori-ku, Yokohama 226-8510, Japan, and D.D.P. Corporation, 1097-3, Kashiya, Kannami-cho, Shizuoka 419-0112, Japan
| | - Satoshi Shuto
- Faculty of Pharmaceutical Sciences, Center for Research and Education on Drug Discovery, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan, PRISM BioLab Co., Ltd., 4259-3, Nagatsuta-cho, Midori-ku, Yokohama 226-8510, Japan, and D.D.P. Corporation, 1097-3, Kashiya, Kannami-cho, Shizuoka 419-0112, Japan
| |
Collapse
|